Miho Takahashi

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Frontiers in Oncology.

PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2021, Cancer Immunology, Immunotherapy.

Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2017, PloS one.

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Translational lung cancer research.

Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations

Y. Ajioka, Hiroshi Tanaka, Miyuki Sato, 2019, PloS one.

Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2021, Scientific Reports.

A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer

F. Gejyo, M. Arakawa, E. Suzuki, 2000, Bone Marrow Transplantation.